Literature DB >> 18164856

Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma.

Daniel R Zwahlen1, Jarad M Martin, Jeremy L Millar, Uwe Schneider.   

Abstract

PURPOSE: To estimate and compare the secondary cancer risk (SCR) due to para-aortic (PA), dogleg field (DLF), or extensive field (EF) radiotherapy (RT) at different dose levels for Stage I testicular seminoma. METHODS AND MATERIALS: The organ equivalent dose concept with a linear, plateau, and linear-exponential dose-response model was applied to the dose distributions to estimate the SCR. The dose distributions were calculated in a voxel-based anthropomorphic phantom. Three different three-dimensional plans were computed: PA, DLF, and EF. The plans were calculated with 6-MV photons and two opposed fields, using 20 Gy in 10 fractions.
RESULTS: The estimated cumulative SCR for a 75-year-old patient treated with PA-RT at age 35 was 23.3% (linear model), 20.9% (plateau model), and 20.8% (linear-exponential model) compared with 19.8% for the general population. Dependent on the model, PA-RT compared with DLF-RT reduced the SCR by 48-63% or 64-69% when normalized to EF-RT. For PA-RT, the linear dose-response model predicted a decrease of 45% in the SCR, using 20 Gy instead of 30 Gy; the linear-exponential dose-response model predicted no change in SCR.
CONCLUSION: Our model suggested that the SCR after PA-RT for Stage I testicular seminoma is reduced by approximately one-half to two-thirds compared with DLF-RT, independent of the dose-response model. The SCR is expected to be equal or lower with 20 Gy than with 30 Gy. In the absence of mature patient data, the organ equivalent dose concept offers the best potential method of estimating the SCR when discussing treatment options with patients.

Entities:  

Mesh:

Year:  2007        PMID: 18164856     DOI: 10.1016/j.ijrobp.2007.10.007

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma.

Authors:  Charles B Simone; Kevin Kramer; William P O'Meara; Justin E Bekelman; Arnaud Belard; James McDonough; John O'Connell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-13       Impact factor: 7.038

2.  Second malignancies in long-term testicular cancer survivors.

Authors:  D Ondrus; M Ondrusova; L Friedova
Journal:  Int Urol Nephrol       Date:  2013-10-06       Impact factor: 2.370

3.  Update on management of seminoma.

Authors:  Emma J Alexander; Ingrid M White; Alan Horwich
Journal:  Indian J Urol       Date:  2010 Jan-Mar

4.  Quasi-IMAT technique and secondary cancer risk in prostate cancer.

Authors:  Judith Alvarez Moret; Oliver Koelbl; Ludwig Bogner
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

Review 5.  Contemporary management of stage I and II seminoma.

Authors:  Peter Chung; Padraig Warde
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 6.  Pure seminoma: a review and update.

Authors:  Noureddine Boujelbene; Adrien Cosinschi; Nadia Boujelbene; Kaouthar Khanfir; Shushila Bhagwati; Eveleyn Herrmann; Rene-Olivier Mirimanoff; Mahmut Ozsahin; Abderrahim Zouhair
Journal:  Radiat Oncol       Date:  2011-08-08       Impact factor: 3.481

Review 7.  Radiotherapy in testicular germ cell tumours - a literature review.

Authors:  Joanna Jonska-Gmyrek; Piotr Peczkowski; Wojciech Michalski; Grazyna Poniatowska; Agnieszka Zolciak-Siwinska; Beata Kotowicz; Pawel Wiechno; Magdalena Golawska; Maria Kowalska; Tomasz Demkow
Journal:  Contemp Oncol (Pozn)       Date:  2017-09-29

8.  Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results.

Authors:  Francesca De Felice; Daniela Musio; Giovanni Luca Gravina; Francesco Marampon; Vincenzo Tombolini
Journal:  Oncotarget       Date:  2016-11-29

9.  Treatment of stage I seminoma: 25 years of experience.

Authors:  Małgorzata Pilichowska; Piotr Pęczkowski; Dorota Rosińska-Okrasa; Barbara Trzaska; Anna Skowrońska-Gardas; Tomasz Demkow
Journal:  Contemp Oncol (Pozn)       Date:  2012-05-29

10.  Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma.

Authors:  A Horwich; S D Fossa; R Huddart; D P Dearnaley; S Stenning; M Aresu; J M Bliss; E Hall
Journal:  Br J Cancer       Date:  2013-11-21       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.